Upstream Bio, Inc. to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug on September 2, 2025

Upstream Bio will release Phase 2 VIBRANT trial data for verekitug on September 2, 2025, focusing on CRSwNP treatment.

Quiver AI Summary

Upstream Bio, Inc., a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, announced it will release top-line data from its Phase 2 VIBRANT trial of verekitug on September 2, 2025. Verekitug is the only known clinical-stage monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor, which plays a role in inflammatory responses. The VIBRANT trial was a global, randomized, placebo-controlled study that assessed the efficacy and safety of verekitug in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). Participants received either the antibody or a placebo every 12 weeks for 24 weeks, with the primary endpoint focusing on the change in endoscopic nasal polyp scores. A conference call and webcast to discuss the results will take place on the same day as the data release. Upstream Bio aims to leverage verekitug's unique properties to meet significant patient needs in conditions like asthma and COPD.

Potential Positives

Upstream Bio will report top-line data from the Phase 2 VIBRANT trial of verekitug, potentially indicating significant advancements in treating severe respiratory disorders.
Verekitug is the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), highlighting its unique position in the drug development landscape.
The company is addressing a substantial unmet need in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD).

Potential Negatives

The press release does not provide any preliminary results or insights from the VIBRANT trial, which could leave investors anxious about the upcoming data report.
There is no mention of any partnerships, collaborations, or funding, which may indicate potential concerns about the company's support and sustainability moving forward.
The release focuses solely on the upcoming data and lacks any information about the company's overall pipeline, which may raise questions about its future prospects beyond verekitug.

FAQ

What is the VIBRANT trial focused on?

The VIBRANT trial focuses on assessing the efficacy and safety of verekitug in adults with chronic rhinosinusitis with nasal polyps (CRSwNP).

When will Upstream Bio report top-line data?

Upstream Bio will report top-line data from the VIBRANT trial on Tuesday, September 2, 2025.

How can I access the conference call and webcast?

The conference call and webcast can be accessed via Upstream Bio’s Investors website or on their Events tab.

What is verekitug?

Verekitug is a clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), developed for inflammatory diseases.

What diseases is Upstream Bio targeting with its treatments?

Upstream Bio is targeting severe respiratory disorders, including chronic rhinosinusitis, severe asthma, and chronic obstructive pulmonary disease (COPD).

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

Full Release

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025.

The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or placebo subcutaneously every 12 weeks for 24 weeks. The primary endpoint was change in endoscopic nasal polyp score (NPS) at Week 24.

Conference Call and Webcast
Upstream Bio’s conference call and webcast to discuss the top-line data results from the Phase 2 VIBRANT trial will begin Tuesday, September 2, 2025, at 8:00 a.m. ET. The live webcast can be accessed via this link or on the Events tab on the Investors section of the Company’s website at https://investors.upstreambio.com/news-events/events . A replay of the webcast will be available on the website following the call.

About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com .